Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial
Richard E. Pratley, Christopher P. Cannon, David Z.I. Cherney, Francesco Cosentino, Darren K. McGuire, Margaret Noyes Essex, David Lawrence, Philip L.S. Jones, Jie Liu, Ingrid Adamsons, Samuel Dagogo-Jack
Dive into the research topics of 'Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial'. Together they form a unique fingerprint.